Preferred Label : olaparib;
MeSH note : an antineoplastic agent;
CISMeF synonym : AZD 2281; OLAPARIB cpd;
MeSH hyponym : AZD2281; AZD-2281;
Is substance : O;
UNII : WOH1JD9AR8;
InChIKey : FDLYAMZZIXQODN-UHFFFAOYSA-N;
Origin ID : C531550;
UMLS CUI : C2316164;
- ATC code(s)
- CISMeF manual mappings
- Exact mapping(s) to DCI
- olaparib [International Nonproprietary Name]
- MeSH indexing information
- MeSH term(s) associated for indexing
- Pharmacological action(s)
- Record concept(s)
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- olaparib [International Nonproprietary Name]
https://www.has-sante.fr/jcms/p_3488172/fr/lynparza-olaparib-cancer-de-l-ovaire
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
olaparib
antineoplastic combined chemotherapy protocols
Bevacizumab/Olaparib Regimen
adult
Carcinoma, Ovarian Epithelial
Stage III Ovarian Cancer AJCC v6 and v7
Stage IV Ovarian Cancer AJCC v6 and v7
fallopian tube neoplasms
peritoneal neoplasms
administration, oral
evaluation of the transparency committee
olaparib
---
https://ansm.sante.fr/tableau-acces-derogatoire/lynparza-100-mg-et-150-mg-comprimes-pellicules
2024
false
false
false
France
French
drug information
olaparib
administration, oral
olaparib
breast neoplasms
HER2-Negative Breast Carcinoma
---
https://www.has-sante.fr/jcms/p_3519904/fr/imfinzi-durvalumab-et-lynparza-olaparib-en-association-cancer-de-l-endometre
2024
false
false
false
France
antineoplastic combined chemotherapy protocols
endometrial neoplasms
evaluation of the transparency committee
durvalumab
olaparib
---
https://www.has-sante.fr/jcms/p_3425643/fr/lynparza-olaparib-cancer-de-la-prostate
2023
false
false
false
France
antineoplastic combined chemotherapy protocols
treatment outcome
insurance, health, reimbursement
abiraterone
prednisone
prednisolone
neoplasm metastasis
adult
metastatic castration resistant prostate cancer
olaparib
antineoplastic agents
guidelines for drug use
administration, oral
evaluation of the transparency committee
olaparib
prostatic neoplasms
---
https://www.has-sante.fr/jcms/p_3411344/fr/lynparza-olaparib-cancer-du-sein-precoce-a-haut-risque-her2-negatif
2023
false
false
false
France
Early Stage HER2-Negative Breast Carcinoma
HER2/Neu Negative
High Risk Breast Carcinoma
breast neoplasms
mutation
treatment outcome
insurance, health, reimbursement
Germline BRCA1 Gene Mutation
Germline BRCA2 Gene Mutation
administration, oral
olaparib
evaluation of the transparency committee
olaparib
breast neoplasms
risk
---
https://www.e-cancer.fr/content/download/443876/6711321/file/MEP_INCA_RecoInhibiteursPARP_vdef.pdf
2022
France
practice guideline
talazoparib
olaparib
Poly(ADP-ribose) Polymerase Inhibitors
talazoparib
rucaparib
olaparib
niraparib
niraparib
olaparib
rucaparib
---
https://www.has-sante.fr/jcms/p_3329237/fr/lynparza-olaparib
https://has-sante.fr/jcms/p_3329245/fr/decision-n-2022-0111/dc/sem-du-31-mars-2022-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-lynparza
2022
false
false
false
France
evaluation of the transparency committee
Lynparza
olaparib
olaparib
olaparib
---
https://www.has-sante.fr/jcms/p_3241358/fr/lynparza-cancer-de-la-prostate-metastatique-resistant-a-la-castration
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
Poly(ADP-ribose) Polymerase Inhibitors
olaparib
administration, oral
prostatic neoplasms, Castration-Resistant
neoplasm metastasis
adult
BRCA1 Gene Mutation
BRCA2 Gene Mutation
evaluation of the transparency committee
olaparib
phthalazines
piperazines
---
https://www.has-sante.fr/jcms/p_3264802/fr/lynparza-olaparib-ovaire
2021
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
olaparib
administration, oral
antineoplastic agents
antineoplastic combined chemotherapy protocols
Bevacizumab/Olaparib Regimen
ovarian neoplasms
fallopian tube neoplasms
carcinoma
Advanced Primary Peritoneal Carcinoma
advanced primary peritoneal cancer
adult
Homologous Recombination Deficiency
phthalazines
piperazines
---
https://www.has-sante.fr/jcms/p_3264984/fr/lynparza-olaparib-prostate
2021
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
administration, oral
metastatic castration resistant prostate cancer
neoplasm metastasis
prostatic neoplasms, Castration-Resistant
antineoplastic agents
olaparib
olaparib
prostatic neoplasms, Castration-Resistant
mutation
genes, BRCA1
genes, BRCA2
phthalazines
piperazines
---
https://www.has-sante.fr/jcms/p_3224943
2020
France
evaluation of the transparency committee
Lynparza
olaparib
olaparib
pancreas
olaparib
---
https://www.ansm.sante.fr/actualites/lynparza-dans-les-cancers-gynecologiques-un-document-pour-guider-les-patientes-lors-du-passage-des-gelules-aux-comprimes
2020
false
false
false
France
French
patients guideline
guidelines for drug use
olaparib
Poly(ADP-ribose) Polymerase Inhibitors
administration, oral
genital neoplasms, female
olaparib
capsules
tablets
phthalazines
piperazines
---
https://ansm.sante.fr/disponibilites-des-produits-de-sante/medicaments/lynparza-50-mg-gelule
2020
false
false
false
France
French
drug information
product recalls and withdrawals
olaparib
olaparib
antineoplastic agents
Carcinoma, Ovarian Epithelial
Serous Tubal Intraepithelial Carcinoma
Primary Peritoneal Carcinoma
fallopian tube neoplasms
peritoneal neoplasms
phthalazines
piperazines
---
https://www.has-sante.fr/portail/jcms/c_2893483/fr/lynparza
2019
false
false
false
France
French
olaparib
olaparib
evaluation of the transparency committee
phthalazines
piperazines
---
https://www.has-sante.fr/jcms/p_3135598/fr/lynparza
2019
false
false
false
France
olaparib
treatment outcome
insurance, health, reimbursement
administration, oral
Carcinoma, Ovarian Epithelial
antineoplastic agents
evaluation of the transparency committee
olaparib
phthalazines
piperazines
---
https://ansm.sante.fr/uploads/2020/10/19/20201019-lettre-hcp-pui-atuc-lynparza.pdf
2019
false
false
false
France
French
pharmacovigilance note
medication errors
tablets
capsules
olaparib
patient education handout
phthalazines
piperazines
---
https://www.has-sante.fr/jcms/p_3135574/fr/lynparza
2019
false
false
false
France
French
evaluation of the transparency committee
insurance, health, reimbursement
treatment outcome
olaparib
olaparib
administration, oral
breast neoplasms
mutation
genes, BRCA1
genes, BRCA2
breast neoplasms
Poly(ADP-ribose) Polymerase Inhibitors
phthalazines
piperazines
---
https://www.ansm.sante.fr/actualites/nouvelle-mesure-dacces-a-linnovation-atu-de-cohorte-dextension-dindication-pour-lutilisation-de-lynparza-100-mg-et-150-mg-comprimes-olaparib-dans-certains-cancers-gynecologiques
2019
false
false
false
France
French
ovarian neoplasms
fallopian tube neoplasms
peritoneal neoplasms
olaparib
olaparib
drug information
antineoplastic agents
advanced primary peritoneal cancer
carcinoma
Maintenance Therapy
phthalazines
piperazines
---
http://www.prescrire.org/Fr/3/31/52057/0/NewsDetails.aspx
2016
false
false
false
France
French
french abstract
survival
olaparib
ovary
life support care
quality of life
olaparib
night time
qualitative
long
advanced
phthalazines
piperazines
---
https://www.ema.europa.eu/medicines/human/EPAR/Lynparza
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
olaparib
olaparib
drug approval
europe
antineoplastic agents
antineoplastic agents
enzyme inhibitors
enzyme inhibitors
orphan drug production
adult
ovarian neoplasms
maintenance chemotherapy
Advanced Malignant Neoplasm
ovarian neoplasms
mutation
genes, BRCA1
genes, BRCA2
Recurrent Ovarian Carcinoma
neoplasm recurrence, local
fallopian tube neoplasms
Malignant Peritoneal Neoplasm
administration, oral
peritoneal neoplasms
Poly(ADP-ribose) polymerases
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
contraception
PARP1 protein, human
PARP2 protein, human
PARP3 protein, human
drug evaluation, preclinical
olaparib
cell cycle proteins
phthalazines
piperazines
phthalazines
piperazines
---
http://www.has-sante.fr/portail/jcms/c_2038097/fr/lynparza
http://www.has-sante.fr/portail/jcms/c_2038097/fr/lynparza-olaparib-inhibiteur-de-l-enzyme-parp
2015
false
false
false
France
French
evaluation of the transparency committee
administration, oral
olaparib
olaparib
treatment outcome
insurance, health, reimbursement
olaparib
adult
ovarian neoplasms
neoplasm recurrence, local
fallopian tube neoplasms
peritoneal neoplasms
enzyme inhibitors
enzyme inhibitors
antineoplastic agents
antineoplastic agents
Poly(ADP-ribose) polymerases
BRCA2 Gene Mutation
BRCA1 Gene Mutation
genes, BRCA1
genes, BRCA2
disease-free survival
Progression-Free survival
mutation
guidelines for drug use
phthalazines
piperazines
phthalazines
piperazines
---